Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Justin Reynolds

Transplant Hepatology Peoria, AZ Medical Doctor

NPI 1568642353 CMS profile 116427

15396 N 83Rd Ave Ste E, Peoria, AZ 85381

Open in the dashboard

General payments

$311,558

462 records reported · program years 2019–2025

Research payments

$1,844

Paid to them · 17 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$624,162 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Justin Reynolds of Peoria, AZ is reported in the CMS Open Payments database as having received $311,558 across 462 general payments and $1,844 in research payments paid to them. Separately, studies naming them as principal investigator received $624,162 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Transplant Hepatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $171,402 193
2024 General $68,957 122
2023 General $13,699 34
2023 Research $1,844 17
2022 General $16,800 37
2021 General $8,045 20
2020 General $8,000 5
2019 General $24,654 51

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Justin Reynolds
  • Transplant Hepatology median
  • Middle half of Transplant Hepatology
  • National median

In program year 2025, general payments to Justin Reynolds were reported at $171,402. Among 195 Transplant Hepatology profiles paid that year, the median was $499 and the middle half received between $124 and $5,839.

Show as a table
Year Justin Reynolds Transplant Hepatology median Middle half National median
2019 $24,654 $386 $98–$3,771 $163
2020 $8,000 $445 $42–$8,101 $114
2021 $8,045 $262 $82–$3,660 $132
2022 $16,800 $323 $125–$3,034 $149
2023 $13,699 $289 $96–$3,037 $160
2024 $68,957 $409 $110–$6,270 $164
2025 $171,402 $499 $124–$5,839 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Madrigal Pharmaceuticals $127,443 124 payments
  2. Gilead Sciences, Inc. $62,401 153 payments
  3. Novo Nordisk Inc $56,742 29 payments
  4. AbbVie, Inc. $37,003 69 payments
  5. Ipsen Biopharmaceuticals, Inc $13,415 21 payments
  6. Eisai Inc. $5,836 11 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $4,050 2 payments
  8. Albireo Pharma, Inc. $2,984 2 payments
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,177 25 payments
  10. Intercept Pharmaceuticals, Inc. $147 8 payments
  11. Other $359 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $231,494 59 payments
  2. Consulting Fee $45,915 17 payments
  3. Travel and Lodging $22,230 96 payments
  4. Food and Beverage $11,905 285 payments
  5. Education $14 5 payments
Products named General payments · program years 2019–2025
  1. REZDIFFRA Liver Disease $92,866 88 payments
  2. Wegovy $41,460 23 payments
  3. MAVYRET $37,003 69 payments
  4. REZDIFFRA Liver Disease $34,477 30 payments
  5. Livdelzi $30,161 39 payments
  6. Epclusa $19,130 28 payments
  7. IQIRVO $13,415 21 payments
  8. Lenvima $5,836 11 payments
  9. Bylvay $2,984 2 payments
  10. XIFAXAN $1,177 25 payments
  11. Other $644 35 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $1,844 17 payments

Prescribing to Medicare patients

Part D · data year 2024 · 38 drugs

Part D claims

1,775

Median for Undefined Physician type: 319

Drug cost

$798,523

Median for Undefined Physician type: $28,032

Branded share of claims

13.8%

Median for Undefined Physician type: 24.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xifaxan Rifaximin Brand 76 $269,629
Ocaliva Obeticholic Acid Brand 16 $217,954
Livdelzi Seladelpar Lysine Brand 11 $140,357
Vemlidy Tenofovir Alafenamide Brand 29 $45,666
Ursodiol Generic 193 $28,077
Tacrolimus Generic 161 $22,481
Cyclosporine Generic 17 $18,157
Everolimus Generic 12 $11,168
Fluconazole Generic 129 $6,221
Tenofovir Disoproxil Fumarate Generic 20 $6,024

The 10 drugs with the highest cost, of 38 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 138 Part D prescribers listed as Undefined Physician type; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$19,694

Medicare's payments for the services billed

Medicare patients

131

Average age 69

Services billed

217

64 women, 67 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 47%
Diabetes 46%
Arthritis 37%
Ischemic heart disease 32%
Osteoporosis 26%
COPD 19%
Atrial fibrillation 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REZDIFFRA
  • Madrigal Pharmaceuticals $34,477
$34,477 — —
Livdelzi
  • Gilead Sciences, Inc. $18,909
$18,909 11 —
Epclusa
  • Gilead Sciences, Inc. $6,252
$6,252 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $129
$129 76 —
MAVYRET
  • AbbVie, Inc. $117
$117 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

479 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Transplant Hepatology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record